| Dr. Fischer
provides Corporate Project and Program Development Consulting
for Pharmaceutical and Biotech companies. He has over
14 years of research and biopharmaceutical industrial
experience ranging from negotiating scientific collaboration
agreements, obtaining venture capital funding, to overseeing
manufacturing, clinical development plans, analytical
methods development and regulatory strategy for development
of biologicals and pharmaceuticals to European and FDA
standards.
Previously, Dr. Fischer was President and CEO for
NatImmune, a biopharmaceutical company which he launched
and grew to 35 employees in 2 years. As President
and CEO, this role encompassed a diverse range of
responsibilities with effective operations in Science,
Manufacturing, Quality, Clinical Development, Regulatory
Affairs, and Market assessments. He was responsible
for the business development, intellectual property
licensing, (in-licensing from academic institutions
and partnering discussions), financing and private
placements and legal documents.
Prior to NatImmune, Dr. Fischer worked for two years
as the Preclinical Manager of Vector Development for
Bavarian Nordic Research Institute. His responsibilities
included preclinical development of vaccinia virus
vectors for vaccine purposes: production/purification
process development; contract manufacture; contract
biosafety testing; lot release/QC testing; contracting
toxicology and biodistribution; regulatory affairs;
and Chemistry, Manufacture and Controls sections of
IND submissions. Dr. Fischer also gained managerial
and financial experience as Head of Preclinical Vector
Development Group, as well as project manager for
academic and clinical collaborations.
Prior to his work with the Bavarian Nordic Research
Institute, Dr. Fischer spent two years working as
a virologist for Biologics Development in Novo Nordisk,
DK. As a virologist, Dr. Fischer was involved in the
development of protein therapeutics to European and
FDA standards. His responsibilities included biosafety
testing, virology validation of biologics production
processes, and management of Contract Research Organizations.
Dr. Fischer received his Doctor of Philosophy (D.
Phil.) in Virology and Biochemistry from Oxford University,
UK and a Masters of Science in Experimental Cellular
Biology from Odense University, Denmark. Prior to
obtaining his Ph.D., Dr. Fisher completed two research
fellows. The first research fellow was with the Department
of G.U. Medicine with St. Mary’s Hospital Medical
School in London. Dr. Fisher studied natural immunity
to HIV. The second research fellow was with the Glycobiology
Institute, University of Oxford, where Dr. Fischer
studied the mechanism of action of an HIV drug undergoing
clinical development by Searle Pharmaceuticals.
Dr. Fischer’s recent work experience entails
in/out-licensing intellectual property rights from
Aarhus University (Denmark), Odense University (Denmark),
Children’s Medical Center Corporation (Boston,
MA), Scripps Research Clinic (La Jolla, CA), Crucell
(Netherlands), Katholieke Universiteit Leuven, (Belgium)
- which accumulates to 14 agreements in total. Dr.
Fischer also provides advice for contract negotiations
for manufacturing, product development and any other
services as needed.
Consistent, thorough and up-to-date analysis of your
evolving needs is just the beginning of CBR’s
commitment to your program. For a comprehensive assessment
of your program requirements, please contact us by
calling (720) 746-1190 or by email at info@cbrintl.com.
|
